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Abstract
Objectives The aim of this study was to compare the morphol-
ogy, radiological stage, conspicuity, and computer-assisted
detection (CAD) characteristics of colorectal cancers (CRC)
detected by computed tomographic colonography (CTC) in
screening and symptomatic populations.
Methods Two radiologists independently analyzed CTC im-
ages from 133 patients diagnosed with CRC in (a) two ran-
domized trials of symptomatic patients (35 patients with 36
tumours) and (b) a screening program using fecal occult blood
testing (FOBt; 98 patients with 100 tumours), measuring tu-
mour length, volume, morphology, radiological stage, and
subjective conspicuity. A commercial CAD package was ap-
plied to both datasets. We compared CTC characteristics be-
tween screening and symptomatic populations with multivar-
iable regression.
Results Screen-detected CRC were significantly smaller
(mean 3.0 vs 4.3 cm, p<0.001), of lower volume (median
9.1 vs 23.2 cm3, p < 0.001) and more frequently polypoid
(34/100, 34 % vs. 5/36, 13.9 %, p=0.02) than symptomatic
CRC. They were of earlier stage than symptomatic tumours
(OR=0.17, 95 %CI 0.07-0.41, p<0.001), and were judged as
significantly less conspicuous (mean conspicuity 54.1/100 vs.
72.8/100, p<0.001). CAD detection was significantly lower
for screen-detected (77.4 %; 95 %CI 67.9-84.7 %) than symp-
tomatic CRC (96.9 %; 95 %CI 83.8-99.4 %, p=0.02).
Conclusions Screen-detected CRC are significantly smaller,
more frequently polypoid, subjectively less conspicuous, and
less likely to be identified by CAD than those in symptomatic
patients.
Key Points
• Screen-detected colorectal cancers (CRC) are significantly
smaller than symptomatic CRC.
• Screening cases are significantly less conspicuous to radiol-
ogists than symptomatic tumours.
• Screen-detected CRC have different morphology compared
to symptomatic tumours (more polypoid, fewer annular).
• A commercial computer-aided detection (CAD) system was
significantly less likely to note screen-detected CRC.
Keywords Colorectal neoplasms . CTcolonography .Mass
screening . Occult blood . Computer-assisted diagnosis
Introduction
Computed tomographic colonography (CTC) is the radiolog-
ical investigation of choice for suspected colorectal neoplasia
because it is highly sensitive for colorectal cancer (CRC) [1]
and adenomas ≥6mm [2–6]. CTC is commonly applied in two
distinct patient groups–firstly, those with symptoms suggest-
ing CRC; and secondly, asymptomatic subjects undergoing
screening. International consensus recommends CTC as suit-
able for investigation of symptomatic patients [7, 8]; a recent
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multicenter randomized trial showed no significant difference
in detection rates of CRC and polyps ≥10 mm between CTC
and colonoscopy [9]. Regarding screening, diagnostic sensi-
tivity of 90 % for CRC and polyps ≥10 mm was achieved in
one large, prospective, multicenter study [10], and a random-
ized trial found higher participation rates at screening CTC
(vs. colonoscopy) [11] that translated to higher per-invitee
advanced adenoma detection rates once surveillance proce-
dures were included [12]. CTC can also be employed in
screening programs using fecal occult blood testing (FOBt)
because it is highly sensitive in this specific scenario [13]. In
such cases, colonic imaging (usually colonoscopy) is reserved
for those testing positive to FOBt—CTC is recommended by
international consensus when colonoscopy is incomplete or
not feasible [7, 8].
Although CTC is now disseminated widely, the compara-
tive morphological features of screen-detected and symptom-
atic cancers have received little attention. Epidemiological
series show that screen-detected cancers are typically of earlier
stage than non-screen detected tumours [14] and have superior
survival [15]. Similarly, cancers detected by screening CTC
are generally of earlier histological stage than the population
average [16]. Intuitively, symptomatic cancers and those de-
tected by screening are likely to have different morphology at
CTC—for example, screening cases being smaller and/or
more subtle, although this is unproven. Additionally, although
computer-assisted detection (CAD) is designed to detect
polyps rather than cancer, many cancers have polypoid fea-
tures and are therefore marked by CAD systems [17]. The
relative performance of standalone CAD in screen-detected
versus symptomatic tumours is also unknown.
In this study we aimed to document and compare the mor-
phology, radiological stage, subjective conspicuity, and CAD
characteristics of cancers detected by CTC in both FOBt
screening and symptomatic populations.
Materials and methods
Permissions
CTC images depicting CRC derived from two sources:
prospective collection via two paired, randomized trials
(the Special Interest Group in Gastrointestinal and
Abdominal Radiology [SIGGAR] trials); and retrospec-
tive collection from a national CRC screening program
(the English Bowel Cancer Screening Programme,
EBCSP). Ethical permission was granted for use of CTC
data for future research in the randomized trials and
waived by the Joint Research Office of the chief investi-
gator for the screening datasets. Patients in the random-
ized studies gave written informed consent.
Patient selection
Symptomatic cases
The SIGGAR trials were parallel, multicenter randomized tri-
als of CTC versus barium enema and CTC versus colonosco-
py in symptomatic patients. Patients aged ≥55 years were
recruited at 21 hospitals following referral for the investiga-
tion of symptoms suggestive of CRC. The primary outcomes
have been published elsewhere [9, 18], and focused on detec-
tion rates of CRC and polyps ≥10 mm [18]; and referral rates
for further testing [9]. No data relating to CTC morphology of
CRC diagnosed in either trial have been reported previously.
For the current study, a trial statistician (KW) identified all
patients who had (a) undergone CTC and (b) were diagnosed
with CRC within the trial. CRC was defined as invasion of
tumour cells into the submucosa or beyond. Anonymized
CTC images were available for 35 patients (derived from 10
different centers), depicting 36 cancers. The images of 62
further patients (with 63 tumours) had not been returned to
the trial office for review.
Screening cases
The EBCSP is a national FOBt-based screening program of
adults aged 60–74 years. CTC is used when colonoscopy is
incomplete or judged unsuitable. We used the program data-
base to identify all individuals screened from April 2006 to
March 2014 who (a) underwent CTC as their first colonic
investigation after a positive FOBt result and (b) were ulti-
mately diagnosed with CRC. We excluded individuals under-
going colonoscopy prior to CTC, since many are requested for
colonic imaging upstream of an obstructing tumour, introduc-
ing spectrum bias toward larger/stenotic tumours. The images
of 98 patients depicting 100 cancers (from 25 different cen-
ters), were transferred to the study office; images of a further
132 patients were requested but not received.
Sample size considerations
The sample size and power calculations for the primary end-
points of the randomized trials have been published previous-
ly [19]. The number of CRC in the symptomatic arm was
dependent on this and therefore fixed. For screening cases,
we assumed a mean tumour length and standard deviation of
3.0 and 1.6 cm, respectively [16], and aimed to estimate tu-
mour length with a confidence interval of 1.5 cm. Using the
approximation N=4*σ2*(Zcrit)
2/D2, where N= sample size,
σ= standard deviation, Zcrit = desired significance criterion,
in this case 1.96 for 5 % significance, and D=desired confi-
dence interval width [20], we required 70 screening cases. We
allowed a 20 % increase for non-normality (i.e., 84 cases). We
ceased attempting to retrieve more screening cases after this
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number had been reached (ultimately, more discs were re-
ceived than anticipated).
CTC imaging procedures
The RCTs required full bowel purgation for CTC, multidetec-
tor acquisition at ≥2.5 mm collimation and dual patient posi-
tioning. Oral fecal tagging agents were discretionary, as was
the use of intravenous contrast. The EBCSP requires
multidetector-row CTC at slice thickness of 1–3 mm and dual
positioning. Fecal tagging, antispasmodics, and the use of
carbon dioxide were recommended at program inception and
mandated since 2012. Intravenous contrast is generally
discouraged unless there is a specific requirement for detailed
extracolonic evaluation. Detailed acquisition parameters are
provided in Supplementary Table 1.
Readers and viewing conditions
CTC dataset order was randomized using the sample com-
mand in R version 3.0.1 (R Foundation for Statistical
Computing, Vienna, Austria). Subsequently, they were
uploaded to both a commercial CTC workstation (Vitrea,
Vital Images, Zoetermeer, The Netherlands) and an open-
source DICOM viewer (Osirix, Pixmeo SARL, Bernex,
Switzerland). Both two-dimensional and three-dimensional
Table 1 Morphology,
dimensions, and subjective
conspicuity of symptomatic and
screen-detected cancers.
Percentages use the number of
tumours of that category (i.e.,
symptomatic or screening) as the
denominator
Screen-detected tumours
(n = 100)
Symptomatic tumours
(n = 36)
p
value
Location 0.52
Left-sided (%) 69 (69.0) 26 (72.2)
Rectum (%) 18 (18.0) 2 (5.6)
Rectosigmoid (%) 9 (9.0) 2 (5.6)
Sigmoid colon (%) 34 (34.0) 18 (50.0)
Descending colon (%) 5 (5.0) 3 (8.3)
Splenic flexure (%) 3 (3.0) 1 (2.8)
Right sided (%) 31 (31.0) 10 (27.8)
Transverse colon (%) 5 (5.0) 1 (2.8)
Hepatic flexure (%) 6 (6.0) 1 (2.8)
Ascending colon (%) 12 (12.0) 3 (8.3)
Cecum (%) 8 (8.0) 5 (13.9)
Morphology 0.02
Non-polypoid 66 (66.0) 31 (86.1) 0.04
Annular (%) 27 (27.0) 21 (58.3)
Non-annular/saddle-shaped (%) 39 (39.0) 10 (27.8)
Polypoid (%) 34 (34.0) 5 (13.9) 0.96
Is; sessile (%) 18 (18.0) 2 (5.6)
Isp; semi-pedunculated (%) 8 (8.0) 1 (2.8)
Ip; pedunculated (%) 7 (7.0) 2 (5.6)
0-IIa; flat (%) 1 (1.0) 0 (0.0)
Luminal stenosis 0.015
Present (%) 17 (17.0) 14 (38.9)
Absent (%) 83 (83.0) 22 (61.1)
Dimensions
Median long axis, cm (IQR) 3.0 (2.1-3.9) 4.3 (3.2-5.3) <0.001
Median thickness/short axis*, cm
(IQR)
1.3 (0.9-1.8) 1.5 (1.2-1.9) 0.07
Median volume, cm3 (IQR) 9.1 (3.5-20.1) 23.2 (9.5-43.6) 0.001
Conspicuity
Reader 1, median (IQR) 75.0 (25.0-86.3) 95.0 (79.5-100) <0.001
Reader 2, median (IQR) 52.0 (25.0-64.0) 70.0 (44.3-75.0) 0.001
*For non-polypoid tumours, dimension given is tumour thickness. For polypoid lesions, dimension given is
orthogonal short axis
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(i.e., endoluminal) displays were available on both platforms
and used in the majority of cases.
Two radiologists (AAP, seven years experience of CTC)
and (FP, two years experience) reviewed the CTC images
independently. Each radiologist used the prone and supine
images (with multiplanar reformatting and endoluminal views
when needed) to record: (a) tumour morphology; either non-
polypoid or polypoid; (b) for polypoid lesions, their sub-type
using the Paris classification [21]: sessile, pedunculated, semi-
pedunculated or flat (<2.5 mm height); (c) for non-polypoid
lesions, whether they were annular (≥90 % of the colonic
circumference) or non-annular; (d) presence/absence of lumi-
nal stenosis (≥50 % diameter reduction versus the immediate-
ly distal colonic segment); (e) tumour dimensions (maximum
multiplanar long axis and orthogonal short axis for polypoid
lesions; long axis and tumour thickness for non-polypoid tu-
mours); (f) radiological T stage, using the TNM 7th edition
[22]; (g) for T3 and T4 lesions, extramural depth of spread
(EMD) beyond the muscularis propria; (h) presence/absence
of radiologically-involved lymph nodes; (i) presence/absence
of vascular invasion; (j) subjective image quality using a com-
bined assessment of bowel cleansing and distension (1=good,
2=moderate or 3= poor); (k) use of fecal tagging; and (l)
subjective conspicuity of the tumour on a 100-point scale
(1 = Bbarely visible^; 100 = Bimmediately obvious^). We
followed the criteria of Burton et al. when determining lymph
node involvement and vascular invasion [23] (nodal
involvement=at least one node ≥1 cm in short axis, or a cluster
of ≥3 nodes within the tumour local vascular pedicle; vascular
invasion=nodular enlargement of colic veins).
Tumour segmental location was extracted from either
SIGGAR trial or EBCSP records and confirmed from the
images by both radiologists. Differences between radiolo-
gists regarding tumour morphology, T stage, EMD, nodal
status, and vascular invasion were resolved by face-to-
face discussion with images available, although we also
recorded each radiologists’ original opinion for assess-
ment of interobserver agreement. Since TNM stage does
not always influence pre-operative treatment decisions,
we also coded all tumours as either good-prognosis or
poor-prognosis tumours, which is both reproducible and
important when considering the administration of neoad-
juvant therapy [24–26]. Specifically, tumours of either T1,
T2, or T3 stage with <5 mm of EMD are regarded as
having a good prognosis, whereas T4 and T3 tumours
with either (a) radiologically-involved lymph nodes or
(b) ≥5 mm of EMD are viewed as having a poor progno-
sis [25, 26].
Since radiologist opinions are inherently subjective, we
generated objective measures of tumour location, ease of de-
tection, and volume. To achieve this, AAP recorded (a)
workstation-derived distance along the colonic centerline
from the anorectal junction to the distal edge of the tumour;
(b) presence/absence of at least one CAD mark within 5 mm
of the tumour in any direction; (c) the total number of CAD
marks for each patient; and (d) tumour volume, calculated by
manually outlining the tumour on each slice and using the
workstation’s volume calculation function. The CAD package
used was iCAD (Nashua, New Hampshire) version 1.4.1.
Statistical analysis
Data were collated using Microsoft Excel 2011 (Microsoft,
Redmond, WA) and analyzed with R version 3.0.1. Since
three patients had more than one tumour, analysis was on a
per-patient basis for patient-level variables (e.g., scan quality,
demographics) and on a per-lesion basis for tumour-level var-
iables (e.g., dimensions, conspicuity).
Patient age and subjective image quality (averaged be-
tween readers) were compared between symptomatic and
screening groups with the Mann-Whitney-Wilcoxon test.
Patient sex and use of fecal tagging were compared using
chi-squared and Fisher exact tests, respectively. To determine
imaging features that differed significantly between symptom-
atic and screen-detected tumours after adjustment for age and
sex, we applied multivariable regressions using linear, binary
logistic, multinominal, or ordered logistic regression as appro-
priate. Tumour dimensions, volumes, and conspicuity scores
were log-transformed to approximate normality prior to
modeling. We used case origin (i.e., symptomatic vs screen-
ing) as the explanatory variable and patient age and sex as
covariates. Image quality was added as a covariate for analysis
of subjective conspicuity.
Agreement between radiologists’ initial independent reads
for tumour stage, nodal stage, and presence of vascular inva-
sion was calculated using quadratic weighted kappa for tu-
mour stage and unweighted kappa for nodal and vascular
stage. Probability values of <0.05 were taken as statistically
significant.
Results
Patient characteristics and CTC image quality
Overall, 133 patients were included; 98 screening (34 fe-
male) with 100 tumours and 35 symptomatic (19 female)
with 36 tumours. Patients in the EBCSP were younger
than those in the RCTs (mean age: 68.2 years versus
71.9, p = 0.02). Subjective image quality was not signifi-
cantly different between the two groups (screening pa-
tients, mean score: 1.5 out of 3; symptomatic patients:
1.4, p = 0.35). Fecal tagging was used for 72/98 patients
in the screening program (73.5 %) but not for any patients
in the randomized trials (0/35 = 0.0 %,p < 0.001).
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Imaging features of tumours
Segmental location and distance from the rectum
Most tumours were left-sided in both groups (screening: 69/
100 tumours, 69.0 %; symptomatic: 26/36 tumours, 72.2 %,
OR=0.78, 95 %CI 0.36-1.69, p=0.52, Table 1, Fig. 1). There
was no significant difference in mean distance along the co-
lonic centerline to the tumour (screening patients:
mean = 68.5 cm; symptomatic patients: mean = 66.3 cm,
p=0.45).
Morphology, dimensions, and volume
Tumour morphology differed significantly between the
two groups; screen-detected tumours were more likely to
be polypoidal than symptomatic tumours (screen-detected:
34/100, 34.0 %; symptomatic: 5/36, 13.9 %, OR=3.80,
95 %CI 1.26-11.49, p = 0.02, Table 1). The Paris classifi-
cation of polypoidal tumours is shown in Table 1, and was
not significantly different between the two groups.
Considering only non-polypoidal tumours, there were sig-
nificantly fewer annular cancers in the screening group
(screen-detected:27/66, 40.9 %; symptomatic:21/31,
67.7 %, OR=0.36, 95 %CI 0.13-0.94, p = 0.04). Screen-
detected cancers were also significantly less likely to
cause ≥50 % luminal stenosis (screen-detected:17/100,
17.0 %; symptomatic: 14/36, 38.9 %, OR=0.33, 95 %CI
0.13-0.81, p = 0.015, Fig. 1). Data for individual radiolo-
gists are provided in Supplementary Table 2.
Tumours in screening patients were also significantly
smaller than those in symptomatic patients. Median long-
axis dimension of screen-detected tumours (averaged between
both radiologists) was 3.0 cm (IQR 2.1-3.9 cm), compared to
4.3 cm (IQR 3.2-5.3 cm) for symptomatic tumours
(p<0.001). Five (5.0 %) screen-detected cancers were less
than 10 mm in long axis whereas none of the symptomatic
cancers measured <10 mm. Tumour volume was also signif-
icantly lower for screen-detected tumours (median 9.1 cm3,
IQR 3.5-20.1 cm3) compared to symptomatic CRC (median
23.2 cm3, IQR 9.5-43.6 cm3, p = 0.001, Table 1, Fig. 2).
Tumours that were detected in the randomized trials, but for
which discs were not available for inclusion in this study
nonetheless had their lengths measured by site radiologists
in the original trials; mean tumour length was measured as
5.2 cm (IQR 3.5-7.0 cm); see Supplementary Table 3.
Relative conspicuity
Screen-detected tumours were judged significantly less con-
spicuous than symptomatic tumours by both radiologists
(Reader 1, screen-detected tumours: median 75.0, symptom-
atic: 95.0, p<0.001; Reader 2, screen-detected: 52.0, symp-
tomatic: 70.0, p = 0.001, Table 1, Fig. 1). Twelve tumours
Fig. 1 Bar charts showing tumour features that were recorded as binary
variables; all charts show the percentage of tumours with (dark grey) or
without (light grey) a given imaging feature. Asterisks indicate statistical
significance at the 5 % level. BAdvanced T stage^ refers to either a T4 or
T3 tumour with ≥5 mm of extramural spread. Scr = screen-detected
tumours, Symp = symptomatic tumours
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were assigned a conspicuity score of ≤10 byReader 1; all were
screen-detected cancers. Reader 2 scored 9 tumours as having
a conspicuity of ≤10; all except one were screen-detected tu-
mours, see Fig. 2.
Sensitivity of standalone CAD
CAD processing was successful for 91/98 (93 %) patients
from the screening program, including both patients with
two tumours, meaning there were 93 screen-detected tumours
for analysis of CAD sensitivity. In total, 30/35 symptomatic
patients (depicting 31 tumours) had successful CAD process-
ing. We were unable to resolve the reason for CAD failure in
the remaining cases.
The total number of CAD marks per patient was not sig-
nificantly different between screening and symptomatic cases
(screening: mean of 19.5 CAD marks/patient, range 4-32;
symptomatic: 19.4 CAD marks/patient, range 6-46,
p = 0.72). However, the proportion of cancers missed by
CAD was significantly greater for screen-detected vs. symp-
tomatic tumours. Specifically, the CAD system identified only
72/93 screen-detected tumours with at least one CAD mark,
giving a standalone sensitivity of 77.4 % (95 %CI 67.9-
84.7 %). Conversely, 30/31 symptomatic tumours were
marked by CAD, giving a significantly higher sensitivity of
96.9 % (95 %CI 83.8-99.4 %, p=0.02, Fig. 3).
There was no significant difference between location, mor-
phology, or size of cancers that were missed by CAD when
compared to those that CAD detected successfully (Table 2).
However, the cancers that were missed by CAD were judged
as significantly less conspicuous than those detected by CAD,
by both readers (Reader 1, median conspicuity score of can-
cers missed by CAD=21.0 (IQR 15.0-60.0) vs. 80.0 (IQR
53.8-94.5) for cancers detected, p<0.001; Reader 2, median
conspicuity of cancers missed byCAD=36.0 (IQR 22.0-57.8)
vs. 58.0 (IQR 40.0-68.8) for cancers detected, p=0.01).
TNM stage and prognostic group
There was Breasonable^ to Bgood^ agreement between radi-
ologists for tumour stage (kappa=0.77), presence of involved
lymph nodes (kappa=0.74) and overall prognostic category
(kappa=0.78). Agreement for the presence of macroscopic
venous invasion was Bmoderate^ (kappa=0.54).
Screen-detected tumours were of significantly earlier radio-
logical local stage than symptomatic tumours (OR=0.17, 95
%CI 0.07-0.41, p<0.001, Table 3). They were also signifi-
cantly less likely to have radiologically involved lymph nodes
(screening 28/100, 28.0 %; symptomatic: 20/36, 55.6 %;
OR=0.31, 95 %CI 0.13-0.72, p=0.006) or macroscopic vas-
cular invasion (screening: 13/100, 13.0 %; symptomatic: 12/
36, 33.3 %,OR=0.26, 95 %CI 0.10-0.67, p =0.01). When
considering the overall CT-derived prognostic group, screen-
ing patients were significantly less likely to have poor-
prognosis tumours (screening: 24/100, 24.0 %;symptomatic:
21/36, 58.3 %, OR=0.21, 95 %CI 0.09-0.50, p<0.001). Data
for individual radiologists are provided in Supplementary
Table 2.
Fig. 2 Examples of different cancers; subtle screening (a), subtle
symptomatic (b), obvious screening (c), and obvious symptomatic (d)
tumours (arrows). In each case, the left panel shows the supine image
and the right panel shows the prone series. The subtle tumours were
assigned a mean conspicuity score of 10 (screening case) and 12
(symptomatic case); the screening case (a) was not detected by CAD.
The obvious tumours were assigned a mean conspicuity score of 97.5
(screening case) and 100 (symptomatic case)
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Discussion
CTC is employed frequently to diagnose CRC, both for pa-
tients with colorectal symptoms and for asymptomatic
screenees. We found significant differences in morphology,
size, volume, and frequency of luminal stenosis between
screen-detected and symptomatic cancers. Furthermore,
screen-detected cancers were of earlier radiological T-stage,
were less likely to have involved lymph nodes or vascular
invasion, and were less likely to meet CT criteria for poor
prognosis. Screen-detected cancers were significantly less
conspicuous than symptomatic CRC, and were less likely to
be identified by a commercial CAD system. Most radiologists
gather initial experience of CTC in symptomatic patients [27].
In this setting, the prevalence of abnormality is high, and we
have shown here that significant abnormalities (i.e., CRC) are
usually obvious. Conversely, screening with CTC is different;
prevalence of abnormality is lower, and even when CRC is
present, it may be very subtle. Therefore, radiologists
embarking on screening CTC, even if they have considerable
experience with symptomatic CTC, may need specific guid-
ance, training, and quality assurance prior to reporting for a
screening program.
CTC is highly sensitive for CRC, with two meta-
analyses suggesting a sensitivity of 96 % [1, 2]. The
CTC features of CRC are well-documented, with the ma-
jority of cancers being either large polyps or masses [16,
28]. However, few reports distinguish between screen-
detected and symptomatic cancers. Regarding screening,
a large USA series reported the findings of colonic and
extracolonic malignancy in 10,286 asymptomatic individ-
uals, describing 22 cases of CRC [16]. Although detailed
morphological parameters of these 22 cancers were not
provided, the authors noted that the majority were large
(mean 3.3 cm) and appeared as Bfrankly invasive masses
or malignant polyps^. Similarly, we found a median size
for screen-detected CRC of 3.0 cm, although five cancers
were subcentimeter and one case of invasive CRC was
found in a 5-mm polyp.
We found significant differences in conspicuity be-
tween screening and symptomatic CRC. A substantial
proportion of screen-detected tumours were judged as
hard to detect, with 14 of 100 cases receiving a conspicu-
ity score of ≤10 by at least one of the radiologists.
Although the Baverage^ or Btypical^ screen-detected can-
cer is relatively obvious (median conspicuity score > 50
for both radiologists), subtle cases of CRC are much more
common in a screening population.
Not only were screen-detected CRCmore difficult to detect
by human readers, the CAD system that we used also had
significantly poorer detection. CAD systems are primarily de-
signed to detect polyps rather than CRC, although many can-
cers have polypoid features and so most CRC are detected by
CAD [17]. While our findings agree with this observation for
symptomatic patients (CAD sensitivity of 96.8 %), we found
that the CAD system used here missed a significant proportion
(22.6 %) of CRC in screenees. We doubt this is due to CTC
data quality, since it was not significantly different between
the two groups. Although fecal tagging was used for most of
the screening cases, and not for the symptomatic cases, CAD
Fig. 3 Example of an upper rectal tumour missed by CAD in a screening patient. Image quality was judged to be good by both readers, with a small
amount of residual fluid which was well-tagged
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systems are designed to operate under such conditions, includ-
ing the system we used [29]. It is more plausible that screen-
detected tumours have inherently different morphologic char-
acteristics that render CAD less effective.We doubt that this is
Table 2 Characteristics of
cancers detected and missed by
the CAD system. All percentages
refer to the proportion of tumours
within that detection category
(i.e., detected or missed)
Number Detected tumours (n = 102) Missed tumours (n = 22) p value
Segmental location 0.44
Left sided (%) 71 (69.6) 14 (63.6)
Rectum (%) 15 (14.7) 4 (18.2)
Rectosigmoid (%) 8 (7.8) 1 (4.5)
Sigmoid colon (%) 37 (36.3) 9 (40.9)
Descending colon (%) 7 (6.9) 0 (0.0)
Splenic flexure (%) 4 (3.9) 0 (0.0)
Right sided (%) 31 (30.4) 8 (36.4)
Transverse colon (%) 4 (3.9) 1 (4.5)
Hepatic flexure (%) 6 (5.9) 1 (4.5)
Ascending colon (%) 10 (9.8) 4 (18.2)
Cecum (%) 11 (10.8) 2 (9.1)
Morphology 0.89
Non-polypoid 72 (70.6) 15 (68.2)
Annular 38 (37.3) 6 (27.3)
Saddle-shaped 34 (33.3) 9 (40.9)
Polypoid 30 (29.4) 7 (31.8)
Is; sessile (%) 17 (16.7) 3 (13.6)
Isp; semipedunculated (%) 5 (4.9) 2 (9.1)
Ip; pedunculated (%) 8 (7.8) 1 (4.5)
0-IIa; flat (%) 0 (0.0) 1 (4.5)
Dimensions
Median long axis, cm (IQR) 3.3 (2.4-4.5) 2.9 (1.7-5.3) 0.74
Median short axis, cm (IQR) 1.3 (1.0-1.8) 1.2 (0.9-1.8) 0.31
Median volume, cm3 (IQR) 12.2 (4.9-27.8) 5.2 (1.5-35.5) 0.94
Conspicuity
Reader 1, median (IQR) 80.0 (53.8-94.5) 21.0 (15.0-60.0) <0.001
Reader 2, median (IQR) 58.0 (40.0-68.8) 36.0 (22.0-57.8) 0.01
Table 3 Radiological tumour
and nodal staging, according to
the TNM 7th edition, presence of
macroscopic vascular invasion,
and overall CT-estimated tumour
prognostic category, split by case
origin (i.e., symptomatic vs.
screening). All percentages use
the number of tumours of that
category as the denominator
Screen-detected tumours (n = 100) Symptomatic tumours (n = 36) p value
Tumour stage <0.001
T1 22 (22.0) 4 (11.1)
T2 47 (47.0) 5 (13.9)
T3 29 (29.0) 24 (66.7)
T4 2 (2.0) 3 (8.3)
Nodal involvement 0.006
Node negative 72 (72.0) 16 (44.4)
Node positive 28 (28.0) 20 (55.6)
Vascular invasion 0.006
Absent 87 (87.0) 24 (66.7)
Present 13 (13.0) 12 (33.3)
Prognostic category <0.001
Good prognosis 76 (76.0) 15 (41.7)
Poor prognosis 24 (24.0) 21 (58.3)
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due to overall gross polyp morphology, since this was not
significantly different between lesions detected and missed
by CAD (Table 2). Instead, it seems likely that there are more
subtle morphological differences between the two groups oth-
er than gross morphology. The cancers missed by CAD were
also judged as subjectively more subtle than those detected, a
finding that agrees with prior work evaluating the conspicuity
of colorectal polyps (as opposed to established CRC) [30]. We
only tested one specific CAD system; other algorithms may
perform differently.
We found that screen-detected cancers were of an earlier
radiological stage than CRC in symptomatic patients. This
agrees with Pickhardt et al., who used screening CTC to
detect CRC at a significantly earlier stage than the US
average [16]. We compared radiological staging rather than
histopathological staging since our primary purpose was to
compare CTC appearances of screen-detected vs. symp-
tomatic cancers; earlier histopathological stage of tumours
detected by CTC following FOBt screening has been re-
ported previously [31].
Our study has limitations. We recruited patients from an
FOBt-based screening program and therefore, by definition,
all patients had occult blood loss. However, it is unlikely that
CRC in the general screening population would be larger than
in FOBt-positive individuals, meaning that our primary con-
clusions regarding the relative size and conspicuity of screen-
detected vs. symptomatic tumours (i.e., the former being
smaller and more subtle) are likely generalizable.
Furthermore, we included only those patients with no prior
colonoscopy (to avoid the inevitable spectrum bias introduced
by including patients with failed colonoscopy, many of whom
will have only undergone CTC because of a colonoscopically-
impassable tumour). There is a small chance that this biased
our cohort toward particularly small or subtle cancers, al-
though this seems unlikely.
Secondly, CTC examinations performed in the SIGGAR
trials did not use fecal tagging, whereas approximately three-
quarters of the EBCSP examinations did. However, this fact
would tend to make symptomatic cancers more difficult to
detect, the exact opposite of what we found. It is plausible that
the differences in contemporary practice are even greater.
Thirdly, conspicuity is necessarily a subjective measure, al-
though we guarded against this by using more than one reader
and employed measurements of tumour size/volume and
CAD detection as more objective outcomes. Nonetheless, it
is important to note that low conspicuity/lack of a CAD mark
does not equate to a failure of detection; 90 % of the 80 CRC
screening cases for which we were provided with radiological
reports were diagnosed at the time of CTC interpretation (or,
conversely, 10 % were missed), compared to 97 % of the
symptomatic cases. Fourthly, we only evaluated these cases
using a single CAD system; it is possible that other algorithms
may have different performance. Although we collated a
relatively large series of CRC for this study, not all CTC data
sets could be retrieved for image review; it is possible that the
cases that we reviewed do not represent the full spectrum of
disease in symptomatic and screening settings. Finally, radio-
logical assessment of both CRC TNM stage and prognostic
category are imperfect, although interreader agreement in our
study was good and compared favorably with existing litera-
ture [25, 26].
In summary, colorectal cancers detected by CTC in an
FOBt screening program were significantly smaller, more
subtle, and of earlier radiological stage than symptomatic tu-
mours. They were also more likely to go undetected by CAD,
which may be of relevance for CAD package design.
Radiologists interpreting both screening and symptomatic
CTC should be aware of the differences in morphology and
conspicuity of CRC that distinguish the two patient
populations.
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